Skip to main content
SP5007,798.99+0.65%DOW53,839.99+0.13%NASDAQ26,803.03+0.81%BTC$62,761.00-1.31%ETH$1,873.23-0.51%GOLD$4,413.40-0.16%OIL$82.07+1.01%
Smart Investors Daily
Sign InSign Up Free
NT

NASDAQ · NTLA

Intellia Therapeutics, Inc.

Healthcare · Biotechnology

$11.83

Down-$0.26 (-2.15%)

Updated Aug 14, 2026, 10:12 AM

SID Score

3.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1B
P/E ratio
-2.36
Dividend yield
0.00%
52-week range
$10.15 – $18.48
Volume
2.95M
Avg. volume
8.04M

Price performance

NTLA price history

1M range · 21 trading sessions · Daily adjusted prices

NTLA closed at $11.83 after 21 trading sessions, down 0.25% for the selected period.

Last close
$11.83
Period change
-0.25%
Period low
$10.67
Period high
$12.09
Daily close
View OHLC price history
NTLA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Aug 13, 2026$12.105$12.1733$11.81$11.832.95M
Aug 12, 2026$12.06$12.31$11.88$12.092.04M
Aug 11, 2026$11.96$12.14$11.69$12.022.57M
Aug 10, 2026$11.80$12.24$11.75$12.023.03M
Aug 7, 2026$11.88$12.08$11.47$11.944.94M
Aug 6, 2026$10.64$11.32$10.64$11.244.34M
Aug 5, 2026$11.31$11.43$10.85$10.974.73M
Aug 4, 2026$10.975$11.335$10.755$11.324.34M
Aug 3, 2026$10.55$10.84$10.40$10.773.32M
Jul 31, 2026$11.13$11.19$10.60$10.682.65M
Jul 30, 2026$10.91$11.13$10.83$11.093.18M
Jul 29, 2026$10.77$11.18$10.5428$10.803.49M
Jul 28, 2026$10.524$10.94$10.15$10.894.86M
Jul 27, 2026$10.99$11.31$10.63$10.672.89M
Jul 24, 2026$11.26$11.32$10.715$10.733.46M
Jul 23, 2026$10.96$11.345$10.92$11.103.77M
Jul 22, 2026$11.25$11.46$11.075$11.132.38M
Jul 21, 2026$11.06$11.56$10.93$11.473.52M
Jul 20, 2026$11.52$11.66$10.91$10.923.74M
Jul 17, 2026$11.73$11.835$11.35$11.3754.33M
Jul 16, 2026$12.43$12.59$11.651$11.866.53M

Latest NTLA news

The latest Smart Investors Daily articles mentioning NTLA.

Stock researchCompany · Overview

NTLA research

Overview

Company profile and research snapshot.

Company profile

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$18.69
Implied upside
—
Analysts
—
NTLA recent ratings
DateFirmRatingTarget
Aug 7, 2026Evercore ISI GroupOutperform—
Jul 16, 2026Wolfe ResearchUnderperform—
Jul 10, 2026WedbushNeutral—
Jun 16, 2026Canaccord GenuityBuy—
Jun 15, 2026HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 7, 2026

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on August 1, 2026, it awarded inducement grants to eight new employees under Intellia’s 2024 Inducement Plan, as amended, as a material inducement to employment. The inducement grants consisted of time-based restricted stock units (“RSUs”) for an aggr

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By